Transoral Incisionless Fundoplication (TIF) Registry Study for Treatment of Gastroesophageal Reflux Disease (GERD)

NCT ID: NCT01118585

Last Updated: 2019-03-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

278 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-05-31

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study objective is to evaluate the safety and efficacy of TIF among a broad range of GERD patients treated in routine clinical practice at multiple centers across the United States.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary Effectiveness Endpoint: Typical and atypical GERD symptom elimination (scores ≤ 2 to each question) or clinically significant improvement (≥ 50% reduction in total scores) at 6-month follow-up compared to baseline.

Secondary Effectiveness Endpoints: GERD symptom elimination or clinically significant improvement at 12-month follow-up, 24-month follow-up and 36-month follow-up; complete discontinuation of PPIs; normalization of esophageal acid exposure; significant reduction in reflux episodes; healing of reflux esophagitis; reduction of hiatal hernia; safety supported by low incidence of serious adverse events.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastroesophageal Reflux Disease Hiatal Hernia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TIF Procedure

Intervention: Transoral incisionless fundoplication procedure using the EsophyX device. During general anesthesia the EsophyX device is introduced trans orally into the stomach and used to created a 270 degree, 3cm in length, wrap at the distal end of the esophagus to treat GERD.. .

Group Type OTHER

TIF Procedure

Intervention Type PROCEDURE

The TIF procedure results in the creation of an esophago-gastric fundoplication extending up to 4 cm above the Z-line and 270 degrees around the esophagus.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TIF Procedure

The TIF procedure results in the creation of an esophago-gastric fundoplication extending up to 4 cm above the Z-line and 270 degrees around the esophagus.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

TIF - Transoral Incisionless fundoplication

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-75 years
* GERD for \> 1 year
* History of daily PPIs use for \> 6 months
* Moderate to severe typical or atypical GERD symptoms off PPIs
* Complete (responders) or partial (nonresponders) symptom control on PPIs
* Deteriorated gastroesophageal junction (Hill grade II or III)
* Proven gastroesophageal reflux by either endoscopy, ambulatory pH or barium swallow testing
* Willingness to undergo pH/impedance testing, if required
* Willingness to cooperate with the postoperative diet for 6 weeks
* Availability for follow up visits at 6 months and 12 months
* Willingly and cognitively signed informed consent

Exclusion Criteria

* BMI \> 35
* Incompletely reducible hiatal hernia with residual of \> 5 mm
* Esophagitis grade D
* Barrett's Esophagus \> 2 cm
* Esophageal ulcer
* Fixed esophageal stricture or narrowing
* Portal hypertension and/or varices
* Active gastro-duodenal ulcer disease
* Gastric outlet obstruction or stenosis
* Gastroparesis or delayed gastric emptying confirmed by solid-phase gastric emptying study, if patient complains of postprandial satiety during assessment
* Coagulation disorder
* History of any of the following: resective gastric or esophageal surgery, antireflux surgery with anatomy unsuitable for TIF procedure per physician judgment, cervical spine fusion, Zenker's diverticulum, esophageal epiphrenic diverticulum, achalasia, scleroderma or dermatomyositis, eosinophilic esophagitis, or cirrhosis
* Pregnancy or plans of pregnancy in the next 12 months
* Enrollment in another device or drug study that may confound the results
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

EndoGastric Solutions

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Reginald CW Bell, MD, FACS

Role: PRINCIPAL_INVESTIGATOR

SurgOne P.C.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mt. Graham Regional Medical Center

Safford, Arizona, United States

Site Status

Tempe St. Luke's Hospital

Tempe, Arizona, United States

Site Status

Swedish Medical Center and SurgOne P.C.

Englewood, Colorado, United States

Site Status

Munroe Regional Hospital

Ocala, Florida, United States

Site Status

St Mary's Hospital

Hobart, Indiana, United States

Site Status

Livingston Hospital and Healthcare Services, Inc. CAH

Salem, Kentucky, United States

Site Status

The Surgeons Group of Baton Rouge

Baton Rouge, Louisiana, United States

Site Status

Allegan Surgical Associates

Allegan, Michigan, United States

Site Status

Crossville Medical Group

Crossville, Tennessee, United States

Site Status

Ihde Surgical Group, PA

Arlington, Texas, United States

Site Status

The University of Texas Health Science Center

Houston, Texas, United States

Site Status

Master Center for Minimally Invasive Surgery

Southlake, Texas, United States

Site Status

Utah County Surgical Associates

Provo, Utah, United States

Site Status

Reston Hospital

Reston, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

http://www.endogastricsolutions.com

Click here for more information about this study: TIF Registry study

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

D00960

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.